Impact of COVID-19 on Radiation Oncology, an Austrian Experience.
Julian MangesiusChristoph Reinhold ArnoldThomas SeppiStephanie MangesiusMario BrügglPaul EichbergerUte GanswindtPublished in: Current oncology (Toronto, Ont.) (2021)
The COVID-19 pandemic has an unprecedented impact on cancer treatment worldwide. We aimed to evaluate the effects of the pandemic on the radiation treatment of patients in order to provide data for future management of such crises. We compared the number of performed radiotherapy sessions of the pandemic period from February 2020 until May 2021 with those of 2018 and 2019 for reference. At our department, no referred patients had to be rejected or postponed, nor any significant changes in fractionation schedules implemented. Nevertheless, there was a substantial drop in overall radiotherapy sessions in 2020 following the first incidence wave of up to -25% (in June) in comparison to previous years. For breast cancer, a maximum decline of sessions of -45% (July) was recorded. Only a short drop of prostate cancer sessions (max -35%, May) followed by a rebound (+42%, July) was observed. Over the investigated period, a loss of 4.4% of expected patients never recovered. The severe impact of COVID-19 on cancer treatment, likely caused by retarded diagnosis and delayed interdisciplinary co-treatment, is reflected in a lower count of radiotherapy sessions. Radiation oncology is a crucial cornerstone in upholding both curative treatment options and treatment capacity during a pandemic.
Keyphrases
- coronavirus disease
- sars cov
- prostate cancer
- end stage renal disease
- early stage
- ejection fraction
- newly diagnosed
- prognostic factors
- chronic kidney disease
- radiation induced
- radiation therapy
- locally advanced
- peritoneal dialysis
- respiratory syndrome coronavirus
- radical prostatectomy
- mass spectrometry
- peripheral blood
- electronic health record
- tertiary care
- high speed